Christine Tkaczyk
Research Subjects
Christine Tkaczyk has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Adam Gamson
4 shared publicationsBret R. Sellman
Early Vaccines and Immune Therapies, AstraZeneca, Gaithersburg, USA
3 shared publicationsBret R Sellman
Bacteriology, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland
2 shared publicationsGeorge Thom
2 shared publicationsKim Rosenthal
Bacteriology, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland
2 shared publicationsOndrej Podlaha
Bioinformatics, Vaccines and Immune Therapies, Biopharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland
2 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Lyophilized monoclonal antibody (mAb) encoded mRNA—lipid nanoparticles (LNPs) lead to stable in vivo expression of mAb after room temperature storage
The recent success of mRNA COVID-19 vaccines using lipid nanoparticles (LNPs) underscores the potential of this technology for delivering gene-encoded biologics in humans. Passive immunization by in vivo expression of monoclonal antibodies (mAbs) could provide advantages over traditional vaccines due to its immediate protection and broader applicability. The use of mRNA allows for rapid development and easily scalable production, while in vivo expression of biologics (IVEB) reduces the complexity and cost associated with traditional mAb manufacturing by leveraging the body as a bioreactor. However, the requirement of cold chain storage and transportation remains a critical challenge for the distribution of mRNA-LNP formulations. Lyophilization of the mRNA-LNP formulations to produce dry powder offers a potential solution to this issue. In this study, we have investigated several lyophilization conditions for mRNA-LNP and evaluated their efficacy both in vitro and in vivo . Further physical stability and structure characterization provided insights into the structure-efficacy relationship. We successfully identified the lyophilization condition using 5 mM Tris buffer at pH 8 with 10% sucrose, which retained LNP particle size within an acceptable range, preserved mRNA encapsulation efficiency, and maintained consistent level of in vivo expressed mAbs after being stored at room temperature for a month.
- 23 March 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Open AccessLyophilized monoclonal antibody (mAb) encoded mRNA—lipid nanoparticles (LNPs) lead to stable in vivo expression of mAb after room temperature storage
The recent success of mRNA COVID-19 vaccines using lipid nanoparticles (LNPs) underscores the potential of this technology for delivering gene-encoded biologics in humans. Passive immunization by in vivo expression of monoclonal antibodies (mAbs) could provide advantages over traditional vaccines due to its immediate protection and broader applicability. The use of mRNA allows for rapid development and easily scalable production, while in vivo expression of biologics (IVEB) reduces the complexity and cost associated with traditional mAb manufacturing by leveraging the body as a bioreactor. However, the requirement of cold chain storage and transportation remains a critical challenge for the distribution of mRNA-LNP formulations. Lyophilization of the mRNA-LNP formulations to produce dry powder offers a potential solution to this issue. In this study, we have investigated several lyophilization conditions for mRNA-LNP and evaluated their efficacy both in vitro and in vivo . Further physical stability and structure characterization provided insights into the structure-efficacy relationship. We successfully identified the lyophilization condition using 5 mM Tris buffer at pH 8 with 10% sucrose, which retained LNP particle size within an acceptable range, preserved mRNA encapsulation efficiency, and maintained consistent level of in vivo expressed mAbs after being stored at room temperature for a month.
- Open Access
- 14 August 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (5) , e741-e752
Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates
Background: Clostridioides difficile toxin B is a virulence factor for C. difficile infections and a clinically validated target for prevention of C. difficile infection recurrence. AZD5148 is a toxin B–neutralizing human monoclonal antibody that binds to an epitope on the toxin B glucosyltransferase domain. Herein, we aim to evaluate the conservation of this binding epitope using a collection of 9134 global C. difficile genomes obtained from a public repository to confirm that residues that are crucial for neutralization are conserved. Methods: Using isolates collected between 2015 and 2023 from 2 independent sources, we performed variant calling, sequence typing, and phylogenetic analysis. We tested in vitro neutralization of cytotoxicity by AZD5148 using 2 cell lines. Results: Herein, we showed that the AZD5148 epitope is highly conserved across all geographic regions and sequence types and has a higher average conservation frequency in its binding site (99.58%) when compared with bezlotoxumab (82.47%). AZD5148 also exhibited broad neutralization in vitro against 8 recently circulating ribotypes. Conclusions: Our comprehensive analysis of global sequences found the AZD5148 epitope to be highly conserved and thus unlikely to be affected by most genotypic variations in recently circulating C. difficile ribotypes and sequence types.
- 14 August 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (5) , e741-e752
Open AccessEpitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates
Background: Clostridioides difficile toxin B is a virulence factor for C. difficile infections and a clinically validated target for prevention of C. difficile infection recurrence. AZD5148 is a toxin B–neutralizing human monoclonal antibody that binds to an epitope on the toxin B glucosyltransferase domain. Herein, we aim to evaluate the conservation of this binding epitope using a collection of 9134 global C. difficile genomes obtained from a public repository to confirm that residues that are crucial for neutralization are conserved. Methods: Using isolates collected between 2015 and 2023 from 2 independent sources, we performed variant calling, sequence typing, and phylogenetic analysis. We tested in vitro neutralization of cytotoxicity by AZD5148 using 2 cell lines. Results: Herein, we showed that the AZD5148 epitope is highly conserved across all geographic regions and sequence types and has a higher average conservation frequency in its binding site (99.58%) when compared with bezlotoxumab (82.47%). AZD5148 also exhibited broad neutralization in vitro against 8 recently circulating ribotypes. Conclusions: Our comprehensive analysis of global sequences found the AZD5148 epitope to be highly conserved and thus unlikely to be affected by most genotypic variations in recently circulating C. difficile ribotypes and sequence types.
- Open Access
- 9 July 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (3) , e421-e430
Structure of ClfA002 in Complex With Neutralizing Antibody AZD7745 Provides Insight into Its Broad Neutralization Mechanism in Staphylococcus aureus Infection
Background: Complications due to Staphylococcus aureus infections are a major health concern as current therapies lack broad coverage; therefore, development of a broad neutralizing therapy is critical. We previously showed that a monoclonal antibody combination comprising suvratoxumab and AZD7745, targeting respectively alpha toxin and clumping factor A (ClfA), 2 S aureus virulence factors, provided broad strain coverage in a mouse model. To understand the basis for the broad strain coverage of AZD7745, the epitope was determined. Moreover, we surveyed a global collection of bacteremia isolates to study AZD7745 epitope conservation and neutralizing activity. Methods: AZD7745 epitope was determined from the co-crystal structure of AZD7745 Fab with the N2N3 fibrinogen binding domain of ClfA (at 1.58 Å). A geographically diverse collection of 174 S aureus bacteremia isolates was collected between 2022 and 2023. Whole genome sequencing was performed to determine the presence of the clfA gene and AZD7745 epitope conservation. AZD7745 neutralizing activity was tested in vitro against a representative strain of each ClfA variant in a fibrinogen/ClfA binding assay. Results: The AZD7745 epitope contains 12 binding residues on the ClfA N3 domain. Among the 174 isolates, we identified 45 ClfA subtypes with 29 presenting amino acid variations on contact residues. Nonetheless, AZD7745 exhibited neutralizing activity against each subtype. We showed that AZD7745 binding to ClfA N3 domain imposes a conformational change that prevents fibrinogen binding to ClfA. Conclusions: ClfA is ubiquitously present on S aureus global clinical isolates, and AZD7745 epitope is highly conserved. This suggests that AZD7745 can confer broad coverage against S aureus.
- 9 July 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (3) , e421-e430
Open AccessStructure of ClfA002 in Complex With Neutralizing Antibody AZD7745 Provides Insight into Its Broad Neutralization Mechanism in Staphylococcus aureus Infection
Background: Complications due to Staphylococcus aureus infections are a major health concern as current therapies lack broad coverage; therefore, development of a broad neutralizing therapy is critical. We previously showed that a monoclonal antibody combination comprising suvratoxumab and AZD7745, targeting respectively alpha toxin and clumping factor A (ClfA), 2 S aureus virulence factors, provided broad strain coverage in a mouse model. To understand the basis for the broad strain coverage of AZD7745, the epitope was determined. Moreover, we surveyed a global collection of bacteremia isolates to study AZD7745 epitope conservation and neutralizing activity. Methods: AZD7745 epitope was determined from the co-crystal structure of AZD7745 Fab with the N2N3 fibrinogen binding domain of ClfA (at 1.58 Å). A geographically diverse collection of 174 S aureus bacteremia isolates was collected between 2022 and 2023. Whole genome sequencing was performed to determine the presence of the clfA gene and AZD7745 epitope conservation. AZD7745 neutralizing activity was tested in vitro against a representative strain of each ClfA variant in a fibrinogen/ClfA binding assay. Results: The AZD7745 epitope contains 12 binding residues on the ClfA N3 domain. Among the 174 isolates, we identified 45 ClfA subtypes with 29 presenting amino acid variations on contact residues. Nonetheless, AZD7745 exhibited neutralizing activity against each subtype. We showed that AZD7745 binding to ClfA N3 domain imposes a conformational change that prevents fibrinogen binding to ClfA. Conclusions: ClfA is ubiquitously present on S aureus global clinical isolates, and AZD7745 epitope is highly conserved. This suggests that AZD7745 can confer broad coverage against S aureus.
- Open Access
- 9 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
A fungal metabolic regulator underlies infectious synergism during Candida albicans-Staphylococcus aureus intra-abdominal co-infection
Candida albicans and Staphylococcus aureus are two commonly associated pathogens that cause nosocomial infections with high morbidity and mortality. Our prior and current work using a murine model of polymicrobial intra-abdominal infection (IAI) demonstrates that synergistic lethality is driven by Candida-induced upregulation of functional S. aureus α-toxin leading to polymicrobial sepsis and organ damage. In order to determine the candidal effector(s) mediating enhanced virulence, an unbiased screen of C. albicans transcription factor mutants was undertaken revealing that zcf13Δ/Δ fails to drive augmented α-toxin or lethal synergism during co-infection. A combination of transcriptional and phenotypic profiling approaches shows that ZCF13 regulates genes involved in pentose metabolism, including RBK1 and HGT7 that contribute to fungal ribose catabolism and uptake, respectively. Subsequent experiments reveal that ribose inhibits the staphylococcal agr quorum sensing system and concomitantly represses toxicity. Unlike wild-type C. albicans, zcf13Δ/Δ did not effectively utilize ribose during co-culture or co-infection leading to exogenous ribose accumulation and agr repression. Forced expression of RBK1 and HGT7 in the zcf13Δ/Δ mutant fully restores pathogenicity during co-infection. Collectively, our results detail the interwoven complexities of cross-kingdom interactions and highlight how intermicrobial metabolism impacts polymicrobial disease pathogenesis with devastating consequences for the host.
- 9 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessA fungal metabolic regulator underlies infectious synergism during Candida albicans-Staphylococcus aureus intra-abdominal co-infection
Candida albicans and Staphylococcus aureus are two commonly associated pathogens that cause nosocomial infections with high morbidity and mortality. Our prior and current work using a murine model of polymicrobial intra-abdominal infection (IAI) demonstrates that synergistic lethality is driven by Candida-induced upregulation of functional S. aureus α-toxin leading to polymicrobial sepsis and organ damage. In order to determine the candidal effector(s) mediating enhanced virulence, an unbiased screen of C. albicans transcription factor mutants was undertaken revealing that zcf13Δ/Δ fails to drive augmented α-toxin or lethal synergism during co-infection. A combination of transcriptional and phenotypic profiling approaches shows that ZCF13 regulates genes involved in pentose metabolism, including RBK1 and HGT7 that contribute to fungal ribose catabolism and uptake, respectively. Subsequent experiments reveal that ribose inhibits the staphylococcal agr quorum sensing system and concomitantly represses toxicity. Unlike wild-type C. albicans, zcf13Δ/Δ did not effectively utilize ribose during co-culture or co-infection leading to exogenous ribose accumulation and agr repression. Forced expression of RBK1 and HGT7 in the zcf13Δ/Δ mutant fully restores pathogenicity during co-infection. Collectively, our results detail the interwoven complexities of cross-kingdom interactions and highlight how intermicrobial metabolism impacts polymicrobial disease pathogenesis with devastating consequences for the host.
- Open Access
- 31 May 2024
- Published by Elsevier in Molecular Therapy
- Vol. 32 (8) , 2505-2518
In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection
- 31 May 2024
- Published by Elsevier in Molecular Therapy
- Vol. 32 (8) , 2505-2518
Open AccessIn vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
683. Understanding Clostridioides difficile toxinB gene conservation through surveillance of public data
Clostridioides difficile infection (CDI) is the leading cause of antibiotic and healthcare-associated infective diarrhea. It is linked to 365,000 infections and causes approximately 20,000 deaths annually in the US. CDI is mediated by the action of toxin B (TcdB) in humans. Monoclonal antibodies (mAbs) that neutralize TcdB function have shown protection against CDI in preclinical models and more recently in the clinic. Several regions on the TcdB gene have been targeted by therapeutic mAbs including the glucosyltransferase (GTD) and the C-terminal combined repetitive oligopeptides (CROPS) domains. We have developed AZD5148, an anti-TcdB mAb targeting a region within the GTD. To understand its strain coverage, we examined sequence variations of GTD including the AZD5148 epitope in contemporary C. difficile strains utilizing a public data repository. 8,085 assembled C. difficile genomes collected between 2015-2022 were obtained from Enterobase. These were annotated with Prokka to identify the TcdB gene coding sequence, and subsequently aligned to the R20291 strain reference. Phylogeny was determined with ParSnp and visualized using iTol. From the aligned sequences, variants were identified using an in-house tool (RADAR). A majority of the C. difficile genomes deposited were from North America, specifically the United States. Ribotype (RT) information was available for 9.6% of the genomes with RT-078 being the most common. Phylogenetic analysis did not reveal any patterns by geography or collection year, though clades tended to be associated with ribotypes. Degree of conservation was calculated at each TcdB genomic residue and was evaluated both regionally and temporally. We found GTD to be highly conserved in US isolates as well as globally. Additionally, among contact residues for AZD5148, any variations observed were single, and were seen for positions 323 (Y-H), 329 (G-E), 349 (V-A), and 350 (L-I). These findings have important implications for drug development including for AZD5148. Specifically, our findings reveal that the GTD domain of the TcdB gene has lower variance globally over the last 7 years making it a promising target for a C. difficile TcdB neutralizing mAb. Kelly Mulholland, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Victoria Godfrey, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Ann Marie Stanley, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Tyler Brady, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Bret R. Sellman, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Christine Tkaczyk, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Vancheswaran Gopalakrishnan, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access683. Understanding Clostridioides difficile toxinB gene conservation through surveillance of public data
Clostridioides difficile infection (CDI) is the leading cause of antibiotic and healthcare-associated infective diarrhea. It is linked to 365,000 infections and causes approximately 20,000 deaths annually in the US. CDI is mediated by the action of toxin B (TcdB) in humans. Monoclonal antibodies (mAbs) that neutralize TcdB function have shown protection against CDI in preclinical models and more recently in the clinic. Several regions on the TcdB gene have been targeted by therapeutic mAbs including the glucosyltransferase (GTD) and the C-terminal combined repetitive oligopeptides (CROPS) domains. We have developed AZD5148, an anti-TcdB mAb targeting a region within the GTD. To understand its strain coverage, we examined sequence variations of GTD including the AZD5148 epitope in contemporary C. difficile strains utilizing a public data repository. 8,085 assembled C. difficile genomes collected between 2015-2022 were obtained from Enterobase. These were annotated with Prokka to identify the TcdB gene coding sequence, and subsequently aligned to the R20291 strain reference. Phylogeny was determined with ParSnp and visualized using iTol. From the aligned sequences, variants were identified using an in-house tool (RADAR). A majority of the C. difficile genomes deposited were from North America, specifically the United States. Ribotype (RT) information was available for 9.6% of the genomes with RT-078 being the most common. Phylogenetic analysis did not reveal any patterns by geography or collection year, though clades tended to be associated with ribotypes. Degree of conservation was calculated at each TcdB genomic residue and was evaluated both regionally and temporally. We found GTD to be highly conserved in US isolates as well as globally. Additionally, among contact residues for AZD5148, any variations observed were single, and were seen for positions 323 (Y-H), 329 (G-E), 349 (V-A), and 350 (L-I). These findings have important implications for drug development including for AZD5148. Specifically, our findings reveal that the GTD domain of the TcdB gene has lower variance globally over the last 7 years making it a promising target for a C. difficile TcdB neutralizing mAb. Kelly Mulholland, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Victoria Godfrey, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Ann Marie Stanley, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Tyler Brady, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Bret R. Sellman, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Christine Tkaczyk, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Vancheswaran Gopalakrishnan, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds
- Open Access
- 29 June 2022
- Published by American Society for Microbiology in mSphere
- Vol. 7 (3) , e0013022
Neutralizing Staphylococcus aureus Virulence with AZD6389, a Three mAb Combination, Accelerates Closure of a Diabetic Polymicrobial Wound
Diabetic foot ulcers (DFU) represent a major complication of diabetes and are associated with poor quality of life and increased morbidity and mortality despite standard of care. They have a complex pathogenesis starting with superficial skin lesions, which often progress to deeper tissue structures up to the bone and ultimately require limb amputation.
- 29 June 2022
- Published by American Society for Microbiology in mSphere
- Vol. 7 (3) , e0013022
Open AccessNeutralizing Staphylococcus aureus Virulence with AZD6389, a Three mAb Combination, Accelerates Closure of a Diabetic Polymicrobial Wound
Diabetic foot ulcers (DFU) represent a major complication of diabetes and are associated with poor quality of life and increased morbidity and mortality despite standard of care. They have a complex pathogenesis starting with superficial skin lesions, which often progress to deeper tissue structures up to the bone and ultimately require limb amputation.